Manuel Lopez-Figueroa

Manuel Lopez-Figueroa is an accomplished professional in the biotechnology and neuroscience fields, currently serving as the Chief Operating Officer for IMIDomics Inc. since June 2015, where the focus is on developing new treatments for immune-mediated inflammatory diseases. In addition, Manuel holds the position of Scientific Liaison at The Pritzker Neuropsychiatric Disorders Research Consortium and has been a board member at Orizon Genomics since May 2020. As a founder and board member of Cantero Therapeutics, formerly Orfan Biotech, Manuel has played a pivotal role since January 2018. Other notable roles include Investment Advisor at Nina Capital since 2019 and Managing Director at Bay City Capital until July 2021. Manuel's academic credentials include a postdoc in CNS from the University of Michigan and a PhD in Neuroscience from the University of Copenhagen, along with a Master's in Molecular and Cellular Biology from Universidad de La Laguna.